Mafenide

Methylated Sulfonamide Antibacterial — DERMATOLOGICALS

Key facts

Mafenide is an ofp drug in the Methylated Sulfonamide Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 1969. DrugCentral lists 31 molecular targets, including CA12, Ca13 and CA7. Recorded indications include Burn Wound Infections.

• Approval status: ofp (first approved 1969 by the FDA).
• Drug class: Methylated Sulfonamide Antibacterial.
• Molecular targets: CA12, Ca13, CA7 and CA (31 listed in DrugCentral).
• Indications: Burn Wound Infections.
• ATC code: D06BA03 (Sulfonamides).
• Molecular formula: C7H10N2O2S; molecular weight 186.23 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Burn Wound Infections

Contraindications (5)

• Anemia due to enzyme deficiency
• Deficiency of glucose-6-phosphate dehydrogenase
• Disorder of lung
• Kidney disease
• Metabolic acidosis

Mechanism & targets

• Established pharmacologic class: Methylated Sulfonamide Antibacterial

Molecular targets (31)

Target	Gene	Action	Activity
Carbonic anhydrase 12	CA12	unknown	Ki 9.52
Carbonic anhydrase 13	Ca13	unknown	Ki 7.39
Carbonic anhydrase 7	CA7	unknown	Ki 7.12
Alpha carbonic anhydrase	CA	unknown	Ki 7.08
Carbonic anhydrase 9	CA9	unknown	Ki 6.99
Carbonic anhydrase	NCE103	unknown	Ki 6.77
Carbonic anhydrase 2	CA2	unknown	Ki 6.77
Carbonic anhydrase 1	CA1	unknown	Ki 6.77
Carbonic anhydrase, alpha family	—	unknown	Ki 6.70
Carbonate dehydratase	—	unknown	Ki 6.46
Carbonic anhydrase	—	unknown	Ki 6.46
Delta carbonic anhydrase	ca1	unknown	Ki 6.37
Carbonic anhydrase	NCE103	unknown	Ki 6.36
Carbonic anhydrase	CA2	unknown	Ki 6.29
Carbonic anhydrase	cynT	unknown	Ki 6.08
Carbonic anhydrase	—	unknown	Ki 6.06
Astrosclerin-3	—	unknown	Ki 6.01
Carbonic anhydrase 15	Ca15	unknown	Ki 6.01
Carbonic anhydrase 4	CA4	unknown	Ki 5.55
Carbonic anhydrase 4	CA4	unknown	Ki 5.55

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1969-01-24	FDA	—	MYLAN INSTITUTIONAL	Yes

ATC classification

ATC code	Therapeutic hierarchy
D06BA03	DERMATOLOGICALS › ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE › CHEMOTHERAPEUTICS FOR TOPICAL USE › Sulfonamides

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: G6PD · Informative PGx

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Mafenide is on its molecule page.

• Molecular formula: C₇H₁₀N₂O₂S
• Molecular weight: 186.23 g/mol
• CAS number: 138-39-6
• InChIKey: TYMRLRRVMHJFTF-UHFFFAOYSA-N
• PubChem CID: 3998

NCC1=CC=C(C=C1)S(N)(=O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Mafenide used for?

DrugCentral lists the following indications for Mafenide: Burn Wound Infections.

How does Mafenide work?

Its molecular targets in DrugCentral include CA12, Ca13, CA7 and CA.

When was Mafenide first approved?

Mafenide was first approved by the FDA in 1969.

What drug class does Mafenide belong to?

Mafenide is in the Methylated Sulfonamide Antibacterial class.

What is the chemical formula of Mafenide?

Mafenide has the molecular formula C7H10N2O2S and a molecular weight of 186.23 g/mol.

Sources

• DrugCentral drug card 1624 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201161 — compound record and bioactivity
• PubChem CID 3998 — chemical identifiers
• DrugBank DB06795 — drug record
• FDA UNII 58447S8P4L — substance identity
• DailyMed: FDA labels for Mafenide — current prescribing information (label search)
• UniProt O43570 (CA12) — target protein
• UniProt P43166 (CA7) — target protein
• UniProt Q16790 (CA9) — target protein
• UniProt P00918 (CA2) — target protein
• UniProt P00915 (CA1) — target protein
• UniProt P22748 (CA4) — target protein
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.